All In Biotech

Drug Trial Radar · NCT03362190

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Oct 11, 2017

Primary completion

Oct 18, 2018

Study completion Oct 18, 2018

Sponsor

Lead sponsor
Ophthotech CorporationIndustry
Sponsor type
Industry
First posted
Dec 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • Avacincaptad PegolDrug

    Avacincaptad Pegol in combination with Lucentis

  • LucentisDrug

    Avacincaptad Pegol in combination with Lucentis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Systemic Adverse EventsTime frame: 6 months
  2. Ophthalmic Adverse EventsTime frame: 6 months

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Retinal Research Institute

    Phoenix, Arizona

  • Retina Centers PC

    Tucson, Arizona

  • Retina Associates SW, PC

    Tucson, Arizona

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retina Consultants of Orange County

    Fullerton, California

  • Retina Consultants of Southern California

    Redlands, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Orange County Retina Medical Group

    Santa Ana, California

  • Colorado Retina Associates

    Golden, Colorado

  • Florida Eye Clinic

    Altamonte Springs, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Illinois Eye Center

    Peoria, Illinois

  • Vitreo Retinal Consultants & Surgeons

    Wichita, Kansas

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • VitreoRetinal Surgery

    Minneapolis, Minnesota

  • Retina Consultants of Nevada

    Henderson, Nevada

  • Sierra Eye Associates

    Reno, Nevada

  • Retina Vitreous Surgeons of CNY, PC

    Syracuse, New York

  • Retina Northwest PC

    Portland, Oregon

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Charleston Neuroscience Institute

    Ladson, South Carolina

  • Retina Research Institute of Texas

    Abilene, Texas

  • Strategic Clinical Research Group

    Willow Park, Texas

  • Peterfy Sandor utcai Korhaz-Rendelointezet es Baleseti Kozpont

    Budapest, Hungary

  • Budapest Retina Associates

    Budapest, Hungary

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szemeszeti Klinika

    Szeged, Hungary

  • Pauls Stradins Clinical University Hospital, Clinic of Ophthalmology

    Riga, Latvia

  • Dr. Solomatin's eye rehabilitation and vision correction centre

    Riga, Latvia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.